Skip to main content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc. — Investor Relations & Filings

Ticker · RFL ISIN · US75062C1009 US Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-10-30 Regulatory Filings
Country US United States of America
Listing US RFL

About Rafael Holdings, Inc.

https://rafaelholdings.com

Rafael Holdings, Inc. is a clinical-stage biotechnology company that invests in and develops therapies for difficult-to-treat diseases. The company holds interests in early-stage and clinical pharmaceutical entities, with a primary focus on novel cancer therapeutics aimed at improving and extending the lives of patients. Following a merger with Cyclo Therapeutics, Rafael Holdings is also advancing a potential breakthrough treatment for Niemann-Pick Type C1, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 Notification of Late Filing submitted to the SEC. It explicitly states that the annual report (Form 10-K) for the period ended July 31, 2024, could not be filed on time due to delays in completing the annual audit. The document is a notification about the late filing of the 10-K report, not the 10-K report itself. It contains no financial data or substantive report content but rather explains the delay and requests an extension. According to the classification rules, such a notification is a Regulatory Filing (RNS) because it is a compliance document notifying the SEC of a late filing rather than the actual annual report.
2024-10-30 English
4
Director's Dealing
2024-10-29 English
4
Director's Dealing
2024-10-29 English
REGISTRATION STATEMENT
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, dated October 9, 2024. It includes a joint proxy statement/prospectus related to a merger between Rafael Holdings, Inc. and Cyclo Therapeutics, Inc. The text discusses the merger agreement, the exchange ratio, stockholder meetings to approve the merger, and details about the securities involved. The document is a comprehensive filing related to a merger transaction and includes proxy solicitation materials and merger consideration details. This type of filing is specifically related to merger and acquisition activity and is not a simple announcement or proxy solicitation alone. Therefore, the appropriate classification is 'Merger & Acquisition' (MA).
2024-10-09 English
AMENDMENT NO. 4 TO SCHEDULE 13D
Major Shareholding Notification
2024-09-30 English
4
Director's Dealing
2024-09-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.